RVLPQ (RVL Pharmaceuticals) EBITDA Margin %: -251.28% (As of Jun. 2023)

What is RVL Pharmaceuticals EBITDA Margin %?

RVL Pharmaceuticals RVLPQ -90.00% 12 EBITDA Margin % is -251.28% as of Jun. 2023. GuruFocus rates RVLPQ with a GF Score™ of 12/100.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. RVL Pharmaceuticals's EBITDA for the three months ended in Jun. 2023 was $-20.75 Mil. RVL Pharmaceuticals's Revenue for the three months ended in Jun. 2023 was $8.26 Mil. Therefore, RVL Pharmaceuticals's EBITDA margin for the quarter that ended in Jun. 2023 was -251.28%.

RVL Pharmaceuticals (OTCPK:RVLPQ) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

RVL Pharmaceuticals EBITDA Margin % Related Terms

RVL Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for RVL Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RVL Pharmaceuticals EBITDA Margin % Chart

RVL Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBITDA Margin %

Get a 7-Day Free Trial

-6.18

-92.82

-250.97

-401.93

-97.00

RVL Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
EBITDA Margin %	Get a 7-Day Free Trial															-127.37	-181.77	-140.02	-46.26	-251.28

RVLPQ vs SNPX, THAR, SLRX: EBITDA Margin % Comparison

For the Biotechnology subindustry, RVL Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RVL Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RVL Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where RVL Pharmaceuticals's EBITDA Margin % falls into.

Save Embed

12GF Score

RVL Pharmaceuticals PLC RVLPQ

EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

RVL Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

RVL Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-48.227	/	49.721
	=	-97.00 %

RVL Pharmaceuticals's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-20.751	/	8.258
	=	-251.28 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -251.28% mean?

RVL Pharmaceuticals (RVLPQ) has a EBITDA Margin % of -251.28% as of Jun. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RVL Pharmaceuticals and its competitors.

Is RVL Pharmaceuticals' EBITDA Margin % too high?

RVL Pharmaceuticals' current EBITDA Margin % is -251.28%. Overall, RVL Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.

How does RVL Pharmaceuticals' EBITDA Margin % compare to SNPX and THAR?

RVL Pharmaceuticals' EBITDA Margin % of -251.28% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on RVL Pharmaceuticals and its competitors. RVL Pharmaceuticals's current EBITDA Margin % is -251.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is RVL Pharmaceuticals stock overvalued right now?

RVL Pharmaceuticals (RVLPQ) has a current EBITDA Margin % of -251.28%. The current EBITDA Margin % is -251.28%. RVL Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For RVL Pharmaceuticals (RVLPQ), the current EBITDA Margin % is -251.28% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RVL Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies SNPX THAR SLRX PHIO PXMD HSTC NVIV IVBT ATNF ENSC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Address 400 Crossing Boulevard, Bridgewater, NJ, USA, 08807

Website https://www.rvlpharma.com

RVL Pharmaceuticals PLC is a pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular medicine and medical aesthetics therapeutic areas. Its revenues consist of product sales, royalty revenues and licensing revenue.

12GF Score

Get the complete analysis for RVLPQ

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View RVLPQ Analysis

See EBITDA Margin % data for all stocks →